利奈唑胺在术后患者中的群体药代动力学:对给药策略的影响。

IF 0.7 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Annum Maha, Mohsin Ali, Hajira Bilal, Muhammad Imran Khokhar, Abdul Muqeet Khan, Rabia Khokhar, Ijaz Alvi, Mamoona Tariq, Mian Waqar Mustafa, Walaa F Alsanie, Abdulhakeem S Alamri, Majid Alhomrani, Muhammad Usman
{"title":"利奈唑胺在术后患者中的群体药代动力学:对给药策略的影响。","authors":"Annum Maha, Mohsin Ali, Hajira Bilal, Muhammad Imran Khokhar, Abdul Muqeet Khan, Rabia Khokhar, Ijaz Alvi, Mamoona Tariq, Mian Waqar Mustafa, Walaa F Alsanie, Abdulhakeem S Alamri, Majid Alhomrani, Muhammad Usman","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Linezolid is a synthetic antibiotic and produces its antibacterial effect by inhibiting protein synthesis. It is used to treat life-threatening infections caused by MRSA and VRE. Linezolid clearance occurs through both the renal and hepatic routes. The identification of factors associated with linezolid clearance is required in Pakistani patients. A total of 215 samples from 59 post-operative patients were collected from a tertiary care hospital after a first dose of linezolid. The data was used to develop a population pharmacokinetic (popPK) model by using NONMEM® software. Analysis of the available covariates on pharmacokinetic parameters of linezolid was performed by using stepwise covariate modeling approach, A one-compartment model described the popPK and the value for linezolid clearance (CL) was 3.72 L/h while that of volume of distribution (Vd) was 36.9 L. The interindividual variability on linezolid CL was 36.5%. During stepwise covariate analysis, creatinine clearance (CRCL) was proved to be a significant covariate on CL. This is concluded that the clearance of linezolid is influenced by the renal status of patients and there is a dire need for dose optimization of linezolid in Pakistani patients based on renal status in order to avoid toxicity and adverse drug effects.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"38 1","pages":"291-298"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Population pharmacokinetics of linezolid among post-operative patients: Implications for dosing strategies.\",\"authors\":\"Annum Maha, Mohsin Ali, Hajira Bilal, Muhammad Imran Khokhar, Abdul Muqeet Khan, Rabia Khokhar, Ijaz Alvi, Mamoona Tariq, Mian Waqar Mustafa, Walaa F Alsanie, Abdulhakeem S Alamri, Majid Alhomrani, Muhammad Usman\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Linezolid is a synthetic antibiotic and produces its antibacterial effect by inhibiting protein synthesis. It is used to treat life-threatening infections caused by MRSA and VRE. Linezolid clearance occurs through both the renal and hepatic routes. The identification of factors associated with linezolid clearance is required in Pakistani patients. A total of 215 samples from 59 post-operative patients were collected from a tertiary care hospital after a first dose of linezolid. The data was used to develop a population pharmacokinetic (popPK) model by using NONMEM® software. Analysis of the available covariates on pharmacokinetic parameters of linezolid was performed by using stepwise covariate modeling approach, A one-compartment model described the popPK and the value for linezolid clearance (CL) was 3.72 L/h while that of volume of distribution (Vd) was 36.9 L. The interindividual variability on linezolid CL was 36.5%. During stepwise covariate analysis, creatinine clearance (CRCL) was proved to be a significant covariate on CL. This is concluded that the clearance of linezolid is influenced by the renal status of patients and there is a dire need for dose optimization of linezolid in Pakistani patients based on renal status in order to avoid toxicity and adverse drug effects.</p>\",\"PeriodicalId\":19971,\"journal\":{\"name\":\"Pakistan journal of pharmaceutical sciences\",\"volume\":\"38 1\",\"pages\":\"291-298\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pakistan journal of pharmaceutical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

利奈唑胺是一种合成抗生素,其抑菌作用是通过抑制蛋白质合成而产生的。它用于治疗MRSA和VRE引起的危及生命的感染。利奈唑胺的清除可通过肾脏和肝脏途径进行。巴基斯坦患者需要确定与利奈唑胺清除率相关的因素。第一次给药利奈唑胺后,从一家三级医院收集了59例术后患者的215份样本。采用NONMEM®软件建立群体药代动力学(popPK)模型。采用逐步协变量建模方法对利奈唑胺药动学参数进行协变量分析,popPK为单室模型,利奈唑胺清除率(CL)为3.72 L/h,分布容积(Vd)为36.9 L,利奈唑胺的个体间变异性为36.5%。在逐步协变量分析中,肌酐清除率(CRCL)被证明是CL的显著协变量。综上所述,利奈唑胺的清除率受患者肾脏状况的影响,巴基斯坦患者迫切需要根据肾脏状况优化利奈唑胺的剂量,以避免毒性和药物不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Population pharmacokinetics of linezolid among post-operative patients: Implications for dosing strategies.

Linezolid is a synthetic antibiotic and produces its antibacterial effect by inhibiting protein synthesis. It is used to treat life-threatening infections caused by MRSA and VRE. Linezolid clearance occurs through both the renal and hepatic routes. The identification of factors associated with linezolid clearance is required in Pakistani patients. A total of 215 samples from 59 post-operative patients were collected from a tertiary care hospital after a first dose of linezolid. The data was used to develop a population pharmacokinetic (popPK) model by using NONMEM® software. Analysis of the available covariates on pharmacokinetic parameters of linezolid was performed by using stepwise covariate modeling approach, A one-compartment model described the popPK and the value for linezolid clearance (CL) was 3.72 L/h while that of volume of distribution (Vd) was 36.9 L. The interindividual variability on linezolid CL was 36.5%. During stepwise covariate analysis, creatinine clearance (CRCL) was proved to be a significant covariate on CL. This is concluded that the clearance of linezolid is influenced by the renal status of patients and there is a dire need for dose optimization of linezolid in Pakistani patients based on renal status in order to avoid toxicity and adverse drug effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
211
审稿时长
4.5 months
期刊介绍: Pakistan Journal of Pharmaceutical Sciences (PJPS) is a peer reviewed multi-disciplinary pharmaceutical sciences journal. The PJPS had its origin in 1988 from the Faculty of Pharmacy, University of Karachi as a biannual journal, frequency converted as quarterly in 2005, and now PJPS is being published as bi-monthly from January 2013. PJPS covers Biological, Pharmaceutical and Medicinal Research (Drug Delivery, Pharmacy Management, Molecular Biology, Biochemical, Pharmacology, Pharmacokinetics, Phytochemical, Bio-analytical, Therapeutics, Biotechnology and research on nano particles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信